{
    "output": [
        [
            "ChemoCentryx",
            "ORG",
            "Announce",
            "Appointment",
            "PERSON"
        ],
        [
            "ChemoCentryx",
            "ORG",
            "Operate_In",
            "Biopharmaceutical Company",
            "ORG"
        ],
        [
            "William (Bill) Fairey",
            "PERSON",
            "Appointed_As",
            "Executive Vice President and Chief Operating Officer",
            "TITLE"
        ],
        [
            "William (Bill) Fairey",
            "PERSON",
            "Lead",
            "Company\u2019s commercial strategy",
            "ACTIVITY"
        ],
        [
            "William (Bill) Fairey",
            "PERSON",
            "Oversee",
            "Other key operational functions of the Company",
            "ACTIVITY"
        ],
        [
            "Thomas J. Schall",
            "PERSON",
            "Said",
            "Bill\u2019s vast experience will serve us well",
            "COMMENT"
        ],
        [
            "William (Bill) Fairey",
            "PERSON",
            "Brings",
            "Over 25 years of substantial pharmaceutical industry commercial experience",
            "FACT"
        ],
        [
            "William (Bill) Fairey",
            "PERSON",
            "Most recent position",
            "President of Actelion Pharmaceuticals U.S.",
            "TITLE"
        ],
        [
            "William (Bill) Fairey",
            "PERSON",
            "Served",
            "Numerous positions with Actelion Pharmaceuticals Ltd",
            "ACTIVITY"
        ],
        [
            "William (Bill) Fairey",
            "PERSON",
            "Started",
            "Pharmaceutical career with Parke-Davis U.S.",
            "ACTIVITY"
        ],
        [
            "William (Bill) Fairey",
            "PERSON",
            "Received",
            "B.S., in Biology from the University of Oregon and M.B.A. from Saint Mary\u2019s College, California",
            "EDUCATION"
        ],
        [
            "ChemoCentryx",
            "ORG",
            "Developing",
            "New medications targeted at inflammatory and autoimmune diseases and cancer",
            "ACTIVITY"
        ],
        [
            "ChemoCentryx",
            "ORG",
            "Targets",
            "Chemokine and chemoattractant systems",
            "ACTIVITY"
        ],
        [
            "ChemoCentryx",
            "ORG",
            "Focusing",
            "On its late stage drug candidates for patients with rare kidney diseases",
            "ACTIVITY"
        ],
        [
            "Avacopan",
            "PRODUCT",
            "Phase III development",
            "For the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA Vasculitis)",
            "ACTIVITY"
        ],
        [
            "Avacopan",
            "PRODUCT",
            "Shown",
            "To be safe, well tolerated and provided effective control of the disease",
            "FACT"
        ],
        [
            "Avacopan",
            "PRODUCT",
            "Being developed",
            "In patients with C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS)",
            "ACTIVITY"
        ],
        [
            "Avacopan",
            "PRODUCT",
            "Granded",
            "Orphan-drug designation for ANCA Vasculitis, C3G and aHUS",
            "FACT"
        ],
        [
            "CCX140",
            "PRODUCT",
            "Being developed",
            "For patients with focal segmental glomerulosclerosis (FSGS)",
            "ACTIVITY"
        ],
        [
            "ChemoCentryx",
            "ORG",
            "Has",
            "Kidney Health Alliance with Vifor Pharma",
            "ACTIVITY"
        ],
        [
            "Vifor Pharma",
            "ORG",
            "Has",
            "Exclusive rights to commercialize avacopan and CCX140 in markets outside of the U.S. and China",
            "ACTIVITY"
        ],
        [
            "ChemoCentryx",
            "ORG",
            "Has",
            "Early stage drug candidates that target chemoattractant receptors in other Inflammatory and autoimmune diseases and in cancer",
            "ACTIVITY"
        ],
        [
            "ChemoCentryx",
            "ORG",
            "Cautions",
            "That statements included in this press release that are not a description of historical facts are forward-looking statements",
            "COMMENT"
        ]
    ]
}